Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SSY Group ( (HK:2005) ) just unveiled an update.
SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of Potassium Chloride and Sodium Chloride Injection. This development marks the second such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by meeting consistency evaluation standards. The injections are used for treating hypokalemia and heart issues caused by digitalis poisoning, potentially impacting the company’s operations positively by expanding its product offerings.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company’s primary products include injections for medical treatments, with a market focus on the People’s Republic of China.
Average Trading Volume: 12,669,784
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.32B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.